Business Context and Reporting Period
Company: Artelo Biosciences, Inc. (Nasdaq: ARTL)
Filing Type: Form 8-K (Current Report)
Date of Report: August 26, 2026
Event: Material modification to rights of security holders via a reverse stock split.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The filing text does not provide a clear value for these items.
Material Changes
- Reverse Stock Split: A one-for-nine (1-for-9) reverse stock split was effected.
- Effective Time: 5:00 p.m. Eastern Time on August 28, 2026.
- Share Count Reduction: Outstanding shares reduced from 4,929,966 to approximately 547,774.
- Authorized Shares: Reduced from 500,000,000 to 55,555,556.
- New CUSIP: 04301G805.
- Fractional Shares: No fractional shares issued; holders entitled to fractions receive one whole share.
- Derivatives: Outstanding warrants and other derivatives automatically adjusted per their terms.
Guidance, Outlook, and Risks
Purpose: The reverse split is intended to improve the marketability and liquidity of the Common Stock.
Forward-Looking Statements: The accompanying press release contains forward-looking statements regarding future performance and expectations. These are subject to substantial risks and uncertainties, and actual results may differ materially from projections. The company disclaims any obligation to update these statements except as required by law.
Investor Verification Checklist
- Verify the new CUSIP number (04301G805) for trading purposes post-split.
- Confirm the adjusted share count in brokerage accounts after the effective time of August 28, 2026.
- Review the terms of any outstanding warrants or derivatives to ensure they have been correctly adjusted.
- Monitor trading volume and price to assess if the split achieves the stated goal of improved liquidity.